首页 | 本学科首页   官方微博 | 高级检索  
检索        

嵌合抗原受体G250-CD8-28BBZ的构建及表达
引用本文:郑骏年,张青,李彩红,杨洁,李慧忠,裴冬生.嵌合抗原受体G250-CD8-28BBZ的构建及表达[J].徐州医学院学报,2013,33(8):511-515.
作者姓名:郑骏年  张青  李彩红  杨洁  李慧忠  裴冬生
作者单位:郑骏年 (); 张青 (徐州医学院肿瘤防治研究所,江苏徐州,221002); 李彩红 (徐州医学院肿瘤防治研究所,江苏徐州221002;徐州医学院第二附属医院放疗科,江苏徐州221002); 杨洁 (徐州医学院肿瘤防治研究所,江苏徐州,221002); 李慧忠 (徐州医学院肿瘤防治研究所,江苏徐州,221002); 裴冬生(徐州医学院肿瘤防治研究所,江苏徐州,221002);
基金项目:江苏省自然科学基金青年项目(项目编号:BK2012146)江苏省高校科研成果产业化推进项目(项目编号:JHB2012-34)
摘    要:目的 构建嵌合抗原受体G250-CD8-28BBZ的慢病毒表达质粒,并研究该嵌合抗原受体在T细胞中的表达.方法 利用常规分子克隆技术将编码Igκ信号肽、抗G250单链抗体及信号结构CD8-28BBZ的编码序列拼接起来,并将得到的融合基因片段插入慢病毒表达载体pLVX-IRES-ZsGreen中,采用酶切及测序鉴定.慢病毒感染T细胞后,通过荧光显微镜、Western blot、流式细胞术检测G250-CD8-28BBZ在T细胞中的表达.结果 双酶切及测序结果显示重组质粒pLVX-G250-CD8-28BBZ构建正确;慢病毒感染后的T细胞能发出绿色荧光;T细胞表达的G250-CD8-28BBZ分子大小正确;慢病毒感染2周后,G250-CD8-28BBZ在T细胞中的阳性表达率为45.2%.结论 成功构建了嵌合抗原受体G250-CD8-28BBZ的慢病毒表达质粒,该嵌合抗原受体能够在T细胞内高效稳定表达.

关 键 词:嵌合抗原受体  肿瘤免疫治疗  G250  慢病毒  T细胞

Construction and expression of chimeric antigen receptor G250-CD8-28BBZ
ZHANG Qing,LI Caihong,LI Huizhong,ZHANG Yang,PEI Dongsheng,ZHENG Junnian.Construction and expression of chimeric antigen receptor G250-CD8-28BBZ[J].Acta Academiae Medicinae Xuzhou,2013,33(8):511-515.
Authors:ZHANG Qing  LI Caihong  LI Huizhong  ZHANG Yang  PEI Dongsheng  ZHENG Junnian
Institution:1. Research Institute of Cancer Prevention and Therapy, Xuzhou Medical College, Xuzhou, Jiangsu 221002, China; 2. Department of Radiotherapy, The Second Affiliated Hospital of Xuzhou Medical College, Xuzhou, Jiangsu 2211302)
Abstract:Objective To construct lentivirus expression plasmid of chimeric antigen receptor (CAR) G250 - CD8 - 28BBZ and detect its expression in T cells. Methods The coding sequences of IgKsignal peptide, the scFv of G250, and signal domain CD8 -28BBZ were spliced by normal molecule cloning techniques. Then, the fusion gene sequence was inserted into the Lentivirus vector pLVX - IRES - ZsGreen. The reconstructed plasmid was identified by restricted enzyme digestion and sequencing. The expression of G250-CD8 -28BBZ in T cells was analyzed by fluorescence obser-vation, Western blot and flow eytometry. Results The results of enzyme digestion and sequencing showed that the cod-ing sequence of G250 - CD8 -28BBZ was right and was inserted into the vector correctly. The results of fluorescence ob-servation, Western blot and flow cytometry showed that T cells were infected successfully, G250-CD8-28BBZ was ex- pressed correctly and G250 - CD8 - 28BBZ + T cells were 45.2%. Conclusion The plasmid PLVX - G250 - CD8 - 28BBZ was constructed successfully. The chimeric antigen receptor G250 - CD8 - 28BBZ could be expressed in T cells efficiently and stably.
Keywords:chimeric antigen receptor  cancer immunotherapy  G250  lentivirus  T cell
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号